Biochemical changes evidenced in alzheimer's disease: A mini-review

Letters in Drug Design and Discovery

Volumn 11, Issue 2, 2014, Pages 240-248

  Scotti, Luciana ^a   Mendonça, Jaime Bezerra ^b   Da Silva, Marcelo Sobral ^c   Pitta, Ivan R ^c   Scotti, Marcus Tullius ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^b STATE UNIVERSITY OF PARAÍBA   (Brazil)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Amyloid plaques; Cholinergic impulse; Dementia; ROS

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; INSULIN; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CHOLINERGIC SYSTEM; GENETIC ASSOCIATION; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84893721290     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/15701808113109990063     Document Type: Article

References (69)

1. Sabuncu, M.R.; Desikan, R.S.; Sepulcre, J.; Yeo, B.T.T.; Liu, H.; Schhmansky, N.J.; Buckner, R.L.; Sperling, R.A.; Fischl, B. The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease. Arch. Neurol., 2011, 68, 1040-1048.
2. Byun, C.J.; Seo, J.; Jo, S.A.; Park, Y.J.; Klug, M.; Rehli, M.; Park, M-H.; Jo, I. DNA methylation of the 50-untranslated region at +298 and +351 represses BACE1 expression in mouse BV-2 microglial cells. Biochem. Bioph. Res. Co., 2012, 417, 387-392.
3. Hamdan, A.C. Avaliação neuropsicológica na doença de Alzheimer e no comprometimento cognitivo leve. Psicol. Argum., 2008, 26, 183-192.
4. Dhikav, V.; Anand, K. Potential Predictors of Hippocampal Atrophy in Alzheimer's Disease. Drug. Aging, 2011, 28, 1-11.
5. Ferrer, I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog. Neurobiol., 2012, 97, 38-51.
6. Mecocci, P.; Polidori, M.C.; Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim.. Bioph.. Acta., 2012, 1822, 631-638.
7. Reitz, C.; Brayne, C.; Mayeux, R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol., 2011, 7, 137-152.
8. Rocchi, A.; Pellegrini, S.; Siciliano, G.; Murri, L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res. Bull., 2003, 61, 1-24.
9. Correia, S.C.; Santos, R.X.; Carvalho, C.; Cardoso, S.; Candeias, E.; Santos, M.S.; Oliveira, C.R.; Moreira, P.I. Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer's disease and diabetes interrelation. Brain Res., 2012, 1441, 64 - 78
10. Thompson, P.A.; Wright, D.E.; Counsell, C.E.; Zajicek, J. Statistical analysis, trial design and duration in Alzheimer's disease clinical trials: a review. Int. Psychogeriatr., 2012, 24, 689-697.
11. Patil, P.O.; Bari, S.B.; Firke, S.D.; Deshmukh, P.K.; Donda, S.T.; Patil, D.A. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease. Bioorg. Med. Chem., 2013, 21, 2434-2450.
12. Henry, M.S.; Passmore, A.P.; Todd, S.; McGuinness, B.; Craig, D.; Johnston, J.A. The development of effective biomarkers for Alzheimer's disease: a review. Int. J. Geriatr. Psych., 2013, 28, 331- 340.
13. Holmes, C. Review: Systemic inflammation and Alzheimer's disease. Neuropath. Appl. Neuro., 2013, 39, 51-68.
14. Hyde,C.; Peters,J.; Bond.M.; Rogers,G.; Hoyle,M.; Anderson, R.; Jeffreys, M.; Davis, S.; Thokala, P.; Moxham, T. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age Ageing., 2013, 42, 14- 20.
15. Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch. Pharm. Res., 2013, 36, 375-399.
16. Mustafa, I.H.; Elkamel, A.; Chen, P.; Ibrahim, G.; Elnashaie, S.S. E. H. Effect of cholineacetyltransferase activity and choline recycle ratio on diffusion-reaction modeling, bifurcation and chaotic behavior of acetylcholine neurocycle and their relation to Alzheimer's and Parkinson's diseases. Chem. Eng. Sci., 2012, 68, 19-35.
17. Bird, T.D.; Stranahan, S.; Sumi, S.M.; Raskind, M. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann. Neurol., 1983, 14, 284-293.
18. Frisoni, G.B. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol., 2010, 6, 67-77.
19. Cowburn, R.F.; Wiehager, B.; Ravid, R.; Winblad, B. Acetylcholine Muscarinic M2 Receptor Stimulated [35S]GTPgS Binding Shows Regional Selective Changes in Alzheimer's Disease Postmortem Brain. Neurodegeneration., 1996, 5, 19-26.
20. Maelicke, A.; Albuquerque, E.X. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur. J. Pharmacol., 2000, 393, 165-170.
21. Narahashi, T.; Marszalec, W.; Moriguchi, S.; Yeh, J. Z.; Zhao, X. Unique mechanism of action of Alzheimer's drugs on brain nicotinic acetylcholine receptors and NMDA receptors. Life Sci., 2003, 74, 281-291.
22. Wevers, A.; Burghaus, L.; Moser, N.; Witter, B.; Steinlein, O.K.; Schütz, U.; Achnitz, B.; Krempel, U.; Nowacki, S.; Pilz, K.; Stoodt, J.; Lindstrom, J.; Vos, R.A.I.D.; Steur, J.; Schröder, H. Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches. Behavioural Brain Res., 2000, 113, 207-215.
23. Remya, C.; Dileep, K.V.; Tintu, I.; Variyar, E.J.; Sadasivan, C. An in silico approach for the identification of inhibitors against Acetylcholinesterase. Med. Chem. Res., 2012, 21, 2779-2787.
24. Ryu, H.W.; Curtis-Long, M.J.; Jung, I.Y.; Kim, D.S.; Kang, K.Y.; Park, K.H. Anticholinesterase potential of flavonols from paper mulberry (Broussonetia papyrifera) and their kinetic studies. Food Chem., 2012, 132, 1244-1250.
25. Chasapis, C.T.; Loutsidou, A.C.; Spiliopoulou, C.A.; Stefanidou, M.E. Zinc and human health: an update. Arch. Toxicol., 2012, 86, 521-534.
26. Bourdel-Marchasson, I.; Delmas-Beauvieux, M.-C.;Peuchant, E.; Richard-Harston, S.; Decamps, A.; Reignier, B.; Emeriau, J.P.; Rainfray, M. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age. Ageing, 2000, 30, 235-241.
27. Pocernich, C. B; Butterfield, D. A. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Bioch. Bioph. Acta., 2012, 625-630.
28. Rinaldi, P.; Polidori, M.C.; Metastasio, A.; Mariani, E.; Mattiolo, P.; Cherubini, A.; Catani, M.; Cecchetti, R.; Senin, U.; Mecocci, P. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol. Aging., 2003, 24, 915-919.
29. Rexroth, S.; Poetsch, A.; Rogner, M.; Hamann, A.; Werner, A.; Osiewacz, H.D.; Schafer, E.R.; Dencher, N.A. Reactive oxygen species target specific tryptophan site in the mitochondrial ATP synthase. Bioch. Bioph. Acta., 2012, 1817, 381-387.
30. Pinnen, F.; Sozio, P.; Cornacchia, C.; Mollica, A.; Iannitelli, A.; D'Aurizio, E.; Cataldi, A.; Zara, S.; Nasuti, C.; Di Stefano, A. Ibuprofen and Glutathione Conjugate as a Potential Therapeutic Agent for Treating Alzheimer's Disease. Arch. Pharm. Chem. Life Sci., 2011, 11, 139-148.
31. Grünblatt, E.; Bartl, J.; Riederer, P. The link between iron, metabolic syndrome, and Alzheimer's disease. J. Neural. Transm., 2011, 118, 371-379.
32. Horan, M. P.; Pichaud, N.; Ballard, J. W. O. Review: Quantifying Mitochondrial Dysfunction in Complex Diseases of Aging. J. Gerontol. A-Biol., 2012, 67, 1022-1035.
33. Morris, J. K.; Burns, J. M. Insulin: An Emerging Treatment for Alzheimer's Disease Dementia?, Curr. Neurol. Neurosci., 2012, 12, 520-527.
34. Xu, W. L.; Von Strauss, E.; Qiu, C. X.; Winblad, B.; Fratiglioni, L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia, 2009, 52, 1031-1039.
35. Puertas, M. C.; Martínez-Martos, J. M.; Carrera, M. P.; Mayas, M. D. Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp. Gerontol., 2012, 47, 625-630.
36. Zhang, C.; Rodriguez, C.; Spaulding, J.; Aw, T. Y.; Feng, J. Age- Dependent and Tissue-Related Glutathione Redox Status in a Mouse Model of Alzheimer's Disease. J. Alzheimers Dis., 2012, 28, 655-666.
37. Konings, C. H.; Kuiper, M. A.; Mulder, C.; Scheltens, Ph.; Wolters, E. Ch. Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J. Neurol. Sci., 1999, 168, 112-115.
38. Cohen, A. D.; Price, J. C.; Weissfeld, L. A.; James, J.; Rosario, B. L.; Bi, W.; Nebes, R. D.; Saxton, J. A.; Snitz, B. E.; Aizestein, H. A.; Wolk, D. A.; Dekosky, S. T.; Mathis, C. A.; Klunk, W. Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve. J. Neurosci., 2009, 25, 14770-1478.
39. Hochman, A.; Gorodin, S.; Korsmeyer, S.; Ziv, I.; Melamed, E.; Offen, D. Enhanced Oxidative Stress and Altered Antioxidants in Brains of Bcl-2-Deficient Mice. J. Neurochem., 1998, 71, 741 -748.
40. Engler, H.; Forsberg, A.; Almkvist, O.; Blomquist, G.; Larsson, E.; Savitcheva, I.; Wall, A.; Ringheim, A.; Langstrom, B.; Nordberg, A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, 2006, 129, 2856-2866.
41. Sano, M.; Bell, K. L.; Galasko, D.; Galvin, J. E.; Thomas, R. G.; Dyck, C. H.; Aisen, P. S. A randomized, double-blind, placebocontrolled trial of simvastatin to treat Alzheimer disease. Neurol., 2011, 77, 556-563.
42. Khan, A.; Vaibhav, K.; Javed, H.; Khan, M.M.; Tabassum, R.; Ahmed, M.E.; Sristava, P.; Khuwaja, G.; Islam, F.; Siddiqui, S.; Shafi, M.M.; Islam, F. Attenuation of Aβ-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. Mol. Cell. Biochem., 2012, 369, 55-65.
43. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. Neuropathological Alterations in Alzheimer Disease. Cold Spring Harb. Perspect. Med., 2011, 1, a006189.
44. Stuble, R.G.; Ala, T.; Patrylo, P.R.; Brewer, G.J.; Yan, X-X. Is brain amyloid production a cause or a result of dementia of the Alzheimer type? J. Alzheimers Dis., 2010, 22, 393-399.
45. Grimm, M.O.W.; Rothhaar, T.L.; Hartmann, T. The role of APP proteolytic processing in lipid metabolism, Exp. Brain Res., 2012, 217, 365-375.
46. Brunholz, S.; Sisodia, S.; Lorenzo, A.; Deyts, C.; Kins, S.; Morfini, G. Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells. Exp. Brain Res., 2012, 217, 353-364.
47. Boyd-Kimball, D.; Sultana, R.; Abdul, H.M.; Butterfield, D.A. Delta;- Glutamylcysteine Ethyl Ester-Induced Up-Regulation of Glutathione Protects Neurons Against Aβ (1-42)-Mediated Oxidative Stress and Neurotoxicity:Implications for Alzheimer's Disease. J. Neurosci. Res., 2005, 79, 700-706.
48. Buerger, K.; Ewers, M.; Pirttila, T.; Zinkowski, R.; Alafuzoff, I.; Teipel, S.J.; DeBernardis, J.; Kerkman, D.; McCulloch, C.; Soininen, H.; Hampel, H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, 2006, 129, 3035-3041.
49. Andreasen, N.; Vanmechelen, E.; Van de Voorde, A.; Davidsson, P.; Tarvonen, S.; Raiha, I.; Sourander, L.; Winblad, B.; Blennow, K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psych., 1998, 64, 298-305.
50. LaFerla, F.M. Amyloid-β and tau in Alzheimer's disease. Nat. Rev. Neurosci., 2008, 9(5), poster.
51. Irwin, D.J.; Cohen, T.J.; Grossman, M.; Arnold, S.E.; Xie, S.X.; Lee, M-Y.; Trojanowski, J.Q.; Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain, 2012, 135, 807-818.
52. Gonzalez, C.; Farias, G.; Maccioni.; R.B. Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules. Cell. Mol. Biol., 1998, 44, 1117-1127.
53. Farias, G.; Gonzalez, C.; Maccioni, R. B. Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau. Mol. Cell. Biochem., 1997, 168, 59-66.
54. Rabinovici, G.D.; Furst, A.J.; Alkalay, A.; Racine, C.A.; O'Neil, J.; Janabi, M.; Baker, S.L.; Agarwal, N.; Bonasera, S.J.; Mormino, E.C.; Weiner, M.W.; Gorno-Tempini, M.L.; Rosen, H.J.; Miller, B.L.; Jagust, W.J. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden, Brain, 2010, 133, 512-528.
55. Kuo, Y-M.; Emmerling, M.R.; Kasunic, T.C.; Kirkpatrick, J.B., Murdoch, G.H.; Ball, M.J.; Roher, A.E. Water-soluble Aβ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains. J. Biol. Chem., 1996, 271, 4077-4081.
56. Amtul, Z.; Uhrig, M.; Wang, L.; Rozmahel, R.F.; Beyreuther, K. Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight. Neurobiol. Aging, 2012, 33, 831.e21-e31.
57. Shen, S.; Callaghan, D.; Juzwik, C.; Xiong, H.; Huang, P.; Zhang, W. ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease. J. Neurochem., 2010, 114, 1590-1604.
58. Blount, J.W.; Ferruzzi, M.; Raftery, D.; Pasiinetti, G. M.; Dixon, R. A. Enzymatic synthesis of substituted epicathechins for bioactivity studies in neurological disorders. Biochem. Bioph. Res. Co., 2012, 417, 457-461.
59. McFall, G. P.; Wiebe, S.A.; Westaway, D.; Jhamandas, J.; Dixon, R. A. IDE (rs6583817) polymorphism and type 2 diabetes differentially modify executive function in older adults. Neurobiol. Aging, 2013, 34, 2208-2216.
60. Quan, Q.; Wang, J.; Li, X.; Wang, Y. Ginsenoside Rg1 Decreases Aβ1-42 Level by Upregulating PPARc and IDE Expression in the Hippocampus of a Rat Model of Alzheimer's Disease. PLOS, 2013, 8, e59155.
61. Carrasquillo, M.M.; Belbin, O.; Zou, F.; Allen M.; Ertekin-Taner, N.; Ansari, M.; Wilcox, S.L.; Kashino, M.R.; Ma, L.; Younkin, L.H.; Younkin, S.G.; Younkin, C.S.; Dincman, T.A.; Howard, M.E.; Howell, C.C.; Stanton, C.M.; Watson, C.M.; Crump, M.; Vitart, V.; Hayward, C.; Hastie, N.D.; Rudan, I.; Campbell, H.; Polasek, O.; Brown, K.; Passmore, P.; Craig, D.; McGuiness, B.; Todd, S.; Kehoe, P.G.; Mann, D.M.; Smith, A.D.; Beaumont, H.; Warden, D.; Holmes, C.; Heun, R.; Kölsch, H.; Kalsheker, N.; Pankratz, V.S.; Dickson, D.W.; Graff-Radford, N.R.; Petersen, R.C.; Wright, A.F.; Youunkin, S.G.; Morgan, K. Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, Aβ, and Alzheimer's Disease. PLOS, 2010, 5, e8764.
62. Killick, R.; Hughes, T. R.; Morgan, B. P.; Lovestone, S. Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH. Neurosci. Lett., 2013, 533, 96-99.
63. Gandy, S.; Haroutunian, V.; Dekosky, S. T.; Sano, M.; Schadt, E. E. CR1 and the "Vanishing Amyloid" Hypothesis of Alzheimer's Disease. Biol. Psychiatry, 2013, 73, 393- 95.
64. Kennedy, B. P.; Bottiglieri, T.; Arning, E.; Ziegler, M. G.; Hansen, L. A.; Masliah, E. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J. Neural. Transm., 2004, 111, 547-567.
65. Serretti, A.; Olgiati, P. Catechol-O-Methyltransferase and Alzheimer's Disease: A Review of Biological and Genetic Findings. CNS Neurol. Disord. Drug. Targets., 2012, 11, 299-305.
66. Laatikainen, L. M.; Sharp, T.; Harrison, P. J.; Tunbridge, E. M. Sexually Dimorphic Effects of Catechol-OMethyltransferase (COMT) Inhibition on Dopamine Metabolism in Multiple Brain Regions. PLOS, 2013, 8, e61839.
67. Giovanni, S.D.; Eleuteri, S.; Paleologou, K.E.; Yin, G.; Zweckestetter, M.; Carrupt, P-A.; Lashuel, H. A. Entacapone and Tolcapone, Two CatecholO-Methyltransferase Inhibitors, Block Fibril Formation of -Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity. J. Biol. Chem., 2010, 285, 1491-1495.
68. Bertolini, F.; Novaroli, L.; Carrupt, P-A.; Reist, M. Novel Screening Assay for Antioxidant Protection against Peroxyl Radical- Induced Loss of Protein Function. J. Pharm. Sci., 2006, 96, 2931- 2944.
69. DeMichele-Sweet, M.A.; Sweet, R.A. Genetics of Psychosis in Alzheimer Disease: A Review. J. Alzheimers Dis., 2010, 19, 761-780.